Iodine
As of the edition of 20 October 2026, Iodine is a small molecule: marketed, first approved in 1964 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1977
- Kind
- Small molecule
- Brand name
- Lipiodol Ultra-fluide
- First approved
- 24 September 1964 (CH)
- Approvals on record
- 13 in 2 regions
- Holder of the most recent approval
- Bayer; 4 holders in all
- Registered trials
- 20, 3 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Hormones; Heart and blood vessels; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 3 | 1 | 1 | 1 |
| Phase 2 | 10 | 6 | 3 | 0 |
| Phase 3 | 4 | 2 | 1 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 20 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Guerbet | Applicant | 1964 to now |
| B. Braun Medical | Later holder | 1980 to now |
| Bayer | Later holder | 1986 to now |
| GE Healthcare | Later holder | 1994 to now |